The COMPASS complex maintains the metastatic capacity imparted by a subpopulation of cells in UPS.

Interestingly, survival analysis in publicly available human data (The Cancer Genome Atlas [TCGA]) showed that human UPS tumors with SETD1A expression above the median expression level had significantly worse survival outcomes ( p = 0.037, Figure 5 B), and a tend toward better survival for tumors expressing CXCL10 that did not reach statistical significance ( Figure 5 C).

also in 111,027 other papers